Eglonil

Fatigue, headaches, depressive states, problems with the heart - Eglonil, a modern neuroleptic, will help smooth out uncomfortable symptoms, or even completely get rid of pathological symptoms. Just do not prescribe it to yourself - this is the job of a qualified specialist. He is the one who can correctly select the dosage and prescribe treatment.

Indications Eglonil

A modern neuroleptic that effectively blocks dopamine receptors is Eglonil. This drug was initially developed by the joint French-Ukrainian company Sanofi Winthrop Industry for Sanofi-Aventis LLC (Ukraine) to effectively relieve problems associated with certain mental disorders in humans.

Main indications for the use of Eglonil:

• Psychoses of various genesis, in the chronic or acute phase of the disease:

• Slowness of thinking.
• A speech disorder that manifests itself in difficulties in producing or perceiving speech sentences (agrammatism).
• Abulia – lack of willpower, lack of initiative, low motivation.
• Confusion of consciousness.
• Absurdity of thoughts, delirium.

• Sluggish schizophrenia is a psychotic personality disorder associated with the breakdown of thought processes and emotional reactions.
• Neuroses of various nature.
• Various psychosomatic diseases:

• Ulcerative lesion of the gastric mucosa and/or duodenum.
• Hemorrhagic rectocolitis.

Release form

On the shelves of modern pharmacies, this medication can be found in a wide range of different dosages, and the form of release is also different.

Depending on the clinical picture of the disease and the patient’s age, the doctor can choose the most effective form and dosage.

1. Release form - a tablet, produced in two types, differing in the concentration of the active substance sulpiride in them: 0.05 g or 0.2 g. Associated chemical compounds are: talc, silicon dioxide, methylcellulose, lactose monohydrate, potato starch, magnesium stearate. Tablets are yellow. On the plane on one side, a dividing groove is clearly visible, and on the other surface, the embossing "SLP200" is visible. A classic cardboard box is produced with one blister, on which there are 12 units of medicine.
2. Solution for intramuscular injection. The concentration of sulpiride (Sulpiridum) in one ampoule is 0.1 g, additional compounds are sulfuric acid, water, sodium chloride. The liquid is colorless and odorless.
3. Release form - yellowish gelatin capsules. Inside the rigid gelatin container is a white, slightly yellowish powder. The concentration of the active substance in the medicine is 0.05 g. The cardboard package contains three blisters, each of which contains 10 units of Eglonil.
4. Solution for internal use, mainly prescribed to small patients (0.5%). 100 ml of the drug contains 0.5 g of the active substance sulpiride. The solution is released in 200 ml glass bottles.

Pharmacodynamics

Small amounts of the active chemical compound have an effect on the patient's body directly on the dopaminergic D1 and D2 receptors of the central nervous system, located mainly on the postsynaptic membrane. Blocking of dopamine receptors occurs selectively, which is a positive factor for therapy. Pharmacodynamics Eglonil is expressed by a fairly moderate neuroleptic effectiveness, which is manifested in the ability to disinhibit the work of nerve impulses. At small administered doses, the drug is considered an effective stimulant and antidepressant. During therapy with sulpiride, no significant sedative effect is observed from the drug in question.

If the dose of the drug is too high and is more than 600 mg per day, the antipsychotic effect of treatment is able to reduce productive symptoms. The manifestation of sedative properties can be observed.

Pharmacokinetics

The expected therapeutic effectiveness with oral administration occurs five hours after administration, with intramuscular parenteral therapeutic treatment - after thirty minutes. After this period, the maximum amount of the active substance in the blood plasma is achieved. When administering 200 mg of the tablet medication, the maximum concentration figure C _max is 0.73 mg / l. In the case of parenteral administration of 100 mg of the solution, the peak amount of the active substance corresponds to approximately 2.2 mg / l.

Pharmacokinetics Eglonil shows a fairly low bioavailability - only about 25 - 35%. Such a percentage range depends on the health condition and sensitivity of the patient's body. Sulpiride shows excellent distribution and penetrating abilities. The highest invasion rate is observed in liver and kidney tissue, but the maximum concentration is found in pituitary cells.

The binding properties of sulpiride with blood proteins is 40%. The active substance of the drug is not metabolized, i.e. no biotransformation occurs with it. The total clearance of the drug, an indicator of the rate of blood plasma purification, is 126 ml per minute.

The half-life (T _1/2 ) of Eglonil is approximately seven hours. Almost all of the drug (about 92%) is excreted through the kidneys in the urine, by glomerular filtration and secretion. About one percent of the administered dose is excreted in breast milk.

Dosing and administration

The medicine of this pharmacological group should be prescribed only by a specialist. The method of application and doses of the medicine in question are prescribed by the attending physician depending on the picture of the disease, the diagnosis and the patient's condition at the time of prescription.

When diagnosing psychosis, Eglonil is prescribed in the form of solutions for intramuscular administration. The drug is administered in a dosage of 0.2 to 0.8 g per day. The duration of therapy is about two weeks.

In case of negative manifestations, sulpiride is taken orally in tablets or capsules - the dose is from 0.2 to 0.6 g daily, for productive symptoms the method of administration is similar, and the daily dosage is prescribed at a rate of 0.8 to 1.6 g.

In case of motor retardation or psychosomatic disorders, the daily amount of Eglonil taken is from 0.1 to 0.2 g.

When diagnosing gastric and/or duodenal ulcers, the gastroenterologist prescribes the patient a medication of 0.15 g per day. The duration of therapy for ulcer diseases is usually from four to six weeks.

For small patients, the medicine is prescribed as a solution for internal administration. The daily dose of the medicine is calculated individually in each case: 5-10 mg per kilogram of the baby's weight. One teaspoon contains 25 mg of solution, and four drops - 1 mg.

Some warnings and recommendations:

1. The medication should be administered no later than four hours before the expected bedtime. This will reduce the risk of insomnia.
2. During the period of treatment with Eglonil, it is advisable to refrain from driving vehicles and potentially dangerous moving mechanisms.
3. Exercise caution when administering the medication if the patient has a history of Parkinson's disease or a tendency to epileptic seizures.
4. Particular caution is required when selecting the dosage in case of renal failure, as well as for children and the elderly.

[ 1 ]

Use Eglonil during pregnancy

There are no contraindications for prescribing the drug in question during pregnancy. However, there is data confirmed by medical statistics that when administering a dose of the drug exceeding 200 mg daily, a small newborn baby may experience a complex of neurological complications manifested by motor disorders (development of extrapyramidal syndrome). Therefore, if it is necessary to use Eglonil during pregnancy or lactation, it is worth reducing the therapeutic dosage and reducing the duration of therapy.

Contraindications

Contraindications to the use of Eglonil are minor and include only:

• Individual intolerance to the components of the medication.
• Pheochromocytoma is a hormonally active tumor of chromaffin cells of the sympathoadrenal system of adrenal or extra-adrenal localization. Or a suspicion of it that has not yet been confirmed or refuted.
• Tendency to allergies.

Side effects Eglonil

When the dosage and method of administration of the drug are observed, side effects of Eglonil occur infrequently. In rare cases, with prolonged therapy or taking significant doses of the drug, the following may be observed:

• Slowness of actions and thought processes.
• Weight gain.
• Problems with libido, female frigidity and male impotence.
• Extrapyramidal disorders.
• Hyperprolactinemia is an increased level of the hormone prolactin in the blood.
• Loss of strength and drowsiness.
• Gynecomastia is an increase in the size of the mammary glands.
• Dyskinesia is a disorder of movement coordination: spasms of the chewing muscles, involuntary movement of the eye pupils, and others.
• Galactorrhea is the secretion of milk or colostrum from the nipples that is not associated with breastfeeding.
• Amenorrhea is the absence of a menstrual cycle.
• Violation of the regulation of vascular tone.
• Malignant neuroleptic complications.

Overdose

If the recommended therapeutic dosages are not observed or there is a medical need to prescribe large quantitative indicators of drug administration, it is possible to obtain large figures of its content in the patient's blood. An overdose of sulpiride can be expressed by the appearance of such negative symptoms:

• Disorder of motor coordination.
• Muscle spasm that can lead to torticollis.
• Visual impairment.
• Nausea.
• Arterial hypertension.
• Increased production of sweat by the secretory glands.
• Dryness of the oral mucosa.
• Weakness, decreased overall tone.
• Extrapyramidal effect.

If one or more symptoms from the above list appear, you should inform your doctor. He may prescribe hemodialysis, which in this situation will bring at least minor relief, or even completely eliminate discomfort. Basic symptomatic therapy is carried out, and the introduction of general anticholinergics is possible.

Interactions with other drugs

The reaction of the patient's body with monotherapy is much easier to predict. Particular caution should be exercised when prescribing complex therapy, in which two or more drugs are used simultaneously. In order to achieve the necessary therapeutic effectiveness, while preventing pathological complications, it is necessary to know the consequences of Eglonil's interaction with other drugs.

Simultaneous administration of sulpiride and such drugs as levodopa, cabergoline and kinagolide is strictly prohibited - they are mutual antagonists. Joint administration with ethanol and other drugs belonging to the sedative group should not be allowed.

The simultaneous administration of benzodiazepines or morphine derivatives with Eglonil has a depressing effect on nerve endings and the speed of impulse reactions.

Particular caution should be exercised when administering Eglonil in tandem with drugs whose pharmacodynamics can provoke a drop in blood pressure.

It is also not recommended to combine the parallel intake with drugs, after the administration of which there is a real risk of developing paroxysmal ventricular tachycardia. Barbiturate drugs can increase the suppression of impulses of the central nervous system.

Combination with the following pharmacological chemical compounds should be avoided:

• Pentamidine.
• Amantadine.
• Antifungal agents.
• Entacapone.
• Disopyramide. Lisuride.
• Lumefantrine.
• Bromocriptine.
• Quinidine.
• Apomorphine.
• Moxifloxacin.
• Selegiline.
• Methadone.
• Halofantrine.
• Sotalol.
• Pramipexole.
• Ibutilide.
• Chlorpromazine.
• Haloperidol.
• Dofetilide.
• Cisapride.
• Erythromycin.
• And other drugs of these pharmacological groups.

Antihypertensive drugs taken together with Eglonil can provoke the development of postural hypotension or a sharp decrease in blood pressure. The combined use of sulpiride with tranquilizers also has a negative effect on the central nervous system.

[ 2 ], [ 3 ]

Storage conditions

To ensure that Eglonil does not lose its therapeutic properties throughout the entire permissible storage period, it is necessary to strictly follow all storage conditions for Eglonil:

• The storage location of the medicinal product should be in a darkened room, protected from direct sunlight.
• Temperature readings should not exceed 30 degrees Celsius.
• The storage location must not be accessible to children.

Shelf life

If all storage conditions for Eglonil have been met, the shelf life of the drug in question is three years. At the same time, after the end of the three-year period, further use of the drug is not allowed, in order to avoid the appearance of negative symptoms.